Infant Formula Science: Why Must ARA Be Added Concurrently With DHA?

Breast milk represents the optimal natural food for infants and serves as the core reference template for infant-formula design. Observant consumers may notice that compliant infant-formula and follow-on-infant-formula products on the market almost always include ARA whenever DHA appears in the ingredient list. Many parents simplistically interpret this practice as "adding an extra nutrient for marketing appeal". Some industry procurement and distribution partners also question: given DHA's higher public profile, why do national food-safety standards impose ratio constraints prohibiting DHA-only fortification?

Mandatory paired addition of DHA and ARA in infant formula is no mere marketing gimmick. It constitutes a technical requirement grounded in infant physiological-metabolic characteristics, breast-milk nutrient profiles and substantial scientific evidence. This article delivers science outreach for general consumers alongside professional reference for raw-material procurement and R&D personnel. It unpacks the underlying rationale for simultaneous DHA-ARA fortification in infant formula and clarifies regulatory requirements, physiological mechanisms and practical purchasing tips.

From the perspective of natural nutritional prototypes, DHA and ARA co-occur inherently within breast milk. Among long-chain polyunsaturated fatty acids in human breast milk, ARA concentrations typically exceed DHA. Their ratio mostly falls within 1:1 ~ 1:2, with the frequently cited optimal reference ratio around 1:1.7. Over millions of years of human evolution, infant brain, retinal and immune-organ development has taken place under this fatty-acid profile. A fundamental design principle of infant formula is to simulate breast-milk nutrient composition as closely as possible. Consequently, when DHA is incorporated into formulations, matching levels of ARA must accompany it to replicate natural dietary patterns rather than delivering isolated single-nutrient supplementation.

Infants' distinct metabolic capacities provide the primary physiological justification for this paired-addition requirement. ARA can be synthesised from linoleic acid, and DHA from α-linolenic acid. However, newborns and young infants exhibit far lower activity of desaturase and elongase enzymes than adults. Their endogenous capacity to produce long-chain polyunsaturated fatty acids remains very limited. These nutrients qualify as conditionally essential and rely heavily on exogenous dietary supply.

More critically, DHA and ARA share one common set of metabolic enzyme systems inside the human body. If infant formula contains high levels of DHA without supplementary ARA, ingested DHA will compete for metabolic-enzyme resources and inhibit the conversion of linoleic acid into ARA, resulting in insufficient infant ARA status. Adults possess substantial metabolic reserves, so this competitive effect exerts comparatively limited influence. In metabolically vulnerable infants, however, such seesaw-type fatty-acid imbalance genuinely occurs. It impairs synthesis of neural-cell and immune-cell membranes and diminishes the physiological benefits of DHA supplementation.

Physiologically, DHA and ARA fulfil distinct yet synergistic roles in infants and cannot substitute for one another. DHA accumulates primarily in retinal and brain synaptic membranes. It enhances cell-membrane fluidity, accelerates nerve-signal transmission, and proves indispensable for visual and cognitive development. ARA, by contrast, accounts for a higher proportion of cerebral-cortex lipids than DHA. It participates in neural-cell proliferation and differentiation, supports synaptic-structure formation, mediates immune-cell responses, and drives tissue growth and repair to sustain infants' rapid physical expansion. DHA facilitates signal conduction; ARA governs cellular construction and growth regulation. Without ARA's complementary presence, DHA cannot fully realise its developmental-promoting physiological value. Multiple infant-feeding intervention trials demonstrate that test infants receiving combined DHA+ARA supplementation achieve superior outcomes in cognitive development and visual-function assessments compared with groups receiving DHA alone.

Chinese national food-safety standards impose explicit mandatory constraints on this nutrient ratio. GB 10765-2021 National Food Safety Standard: Infant Formula and GB 10766-2021 National Food Safety Standard: Follow-up Formula for Older Infants and Young Children clearly stipulate: where DHA is added to a formula, ARA content shall not be lower than DHA content. Meanwhile, a maximum ARA limit is enforced to prevent over-fortification (≤19.1 mg per 100 kJ). This regulatory provision prevents manufacturers from pursuing DHA-centric marketing by elevating DHA levels while neglecting ARA, which would induce fatty-acid imbalance and compromise infant nutritional safety. It represents a non-negotiable red line for infant-formula product development. When reviewing formulations, screening OEM partners and evaluating raw-material schemes, procurement professionals must verify this specification rather than focusing solely on DHA concentrations.

A common misconception requires correction: higher ARA addition does not equal better performance. While national standards demand ARA ≥ DHA, they simultaneously set an upper concentration threshold. Formulations should stay within breast-milk-referenced ratio ranges; indiscriminate ultra-high ARA fortification will likewise disrupt fatty-acid equilibrium.

For ordinary consumers, understanding this logic helps avoid purchasing pitfalls. Many parents compare only DHA values when selecting formula milk and assume higher DHA always indicates superior quality, overlooking ARA entirely. In practice, when choosing infant-formula products, first confirm compliance with national standards. Verify that ARA accompanies added DHA and their ratio approximates the breast-milk reference of 1:1 ~ 1:1.7 for optimal outcomes; do not fixate obsessively on maximised DHA figures.

For procurement specialists, brand managers and formulation R&D staff, several operational recommendations apply:

1. Strictly comply with national-standard requirements: whenever DHA is incorporated into a formula, ARA content must not fall below DHA content - this marks the compliance baseline for formulations.

2. Prefer Mortierella-fermented ARA-oil raw materials; rigorously assess quality-control parameters including oxidation indices, microbiological status and mycotoxin risks.

3. Conduct objective product communication explaining DHA-ARA synergies; refrain from efficacy exaggeration and reject marketing narratives claiming "higher DHA is always better".

4. Train distribution-channel partners on infant physiological principles underpinning regulatory rules, equipping them to answer the frequently-asked end-consumer question "why is ARA added?".

To conclude, the regulatory requirement for concurrent ARA addition alongside DHA in infant-formula foods originates from natural breast-milk nutrient patterns, infant-specific metabolic competition mechanisms, and enforceable national food-safety standards. It is not merely "adding one extra nutrient for selling points". This rule mitigates fatty-acid metabolic-imbalance risks stemming from DHA-only fortification and safeguards balanced infant development of vision, brain, physique and immunity. Consumers should evaluate full formula profiles instead of fixating only on DHA; industry professionals developing products should resist chasing marketing fads. Adherence to the breast-milk nutritional prototype and compliance with statutory nutrient ratios constitute the core principles for infant-formula development.

References

[1] Chinese Nutrition Society. Chinese Dietary Reference Intakes (2023 Edition) [M]. Beijing: People's Medical Publishing House, 2023.

[2] Yang Yuexin. Chinese Encyclopedia of Nutrition Science (2nd Edition) [M]. Beijing: People's Medical Publishing House, 2019.

[3] Yin Shian. Human Milk Composition: Forms, Contents, Functions and Detection Methods [M]. Beijing: Chemical Industry Press, 2016.

[4] GB 10765-2021, National Food Safety Standard: Infant Formula [S]. Beijing: National Health Commission of the People's Republic of China, 2021.

[5] Hadley K B, Ryan A S, Forsyth S, et al. The essentiality of arachidonic acid in infant development [J]. Nutrients, 2016, 8(4):216.

[6] Birch E E, Garfield S, Hoffman D R, et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants [J]. Developmental Medicine and Child Neurology, 2000, 42(3):174-181.

[7] Expert Group on DHA Supplementation for Chinese Pregnant, Lactating Women and Infants. Expert consensus on DHA supplementation for Chinese pregnant, lactating women and infants [J]. Chinese Journal of Reproductive Health, 2015, 26(2):101-105.

[8] Koletzko B, et al. Current information and Asian perspectives on long-chain polyunsaturated fatty acids in pregnancy, lactation, and infancy [J]. Annals of Nutrition and Metabolism, 2014, 65:49-80.